Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) Director Sells $298,368.00 in Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak sold 19,200 shares of the business’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $15.54, for a total value of $298,368.00. Following the completion of the transaction, the director directly owned 191,763 shares of the company’s stock, valued at approximately $2,979,997.02. The trade was a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Dennis Podlesak also recently made the following trade(s):

• On Monday, August 18th, Dennis Podlesak sold 19,200 shares of Syndax Pharmaceuticals stock. The stock was sold at an average price of $15.84, for a total value of $304,128.00.

Syndax Pharmaceuticals Trading Up 2.2%

SNDX opened at $15.74 on Thursday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -4.05 and a beta of 0.74. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $22.50. The stock has a fifty day moving average price of $10.63 and a 200-day moving average price of $11.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.18. The firm had revenue of $37.96 million during the quarter, compared to analyst estimates of $26.64 million. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The business’s revenue for the quarter was up 984.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.80) EPS. As a group, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SNDX. UBS Group reduced their target price on Syndax Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, July 15th. BTIG Research upped their target price on Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Citigroup upped their target price on Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Wall Street Zen raised Syndax Pharmaceuticals to a “sell” rating in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group began coverage on Syndax Pharmaceuticals in a research report on Thursday, July 10th. They set a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $38.00.

Institutional Trading of Syndax Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its stake in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after purchasing an additional 827 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Syndax Pharmaceuticals by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company’s stock valued at $706,000 after purchasing an additional 1,811 shares during the last quarter. Quarry LP purchased a new stake in Syndax Pharmaceuticals during the 1st quarter valued at about $25,000. Teacher Retirement System of Texas grew its stake in Syndax Pharmaceuticals by 11.9% during the 2nd quarter. Teacher Retirement System of Texas now owns 23,132 shares of the company’s stock valued at $217,000 after purchasing an additional 2,458 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Syndax Pharmaceuticals by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,149 shares of the company’s stock valued at $413,000 after purchasing an additional 2,479 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).